| Ytd | -31.47% | |
| 1y | -34.35% |
| Open | 12.16 | Prev Close | 12.18 | Low | 12.02 | High | 12.20 | Mkt Cap | 510.93M |
| Vol | 7.68K | Avg Vol | 773.47K | EPS | -38.52 | P/E | -0.31 | Forward P/E | -10.51 |
| Beta | N/A | Short Ratio | 5.58 | Inst. Own | 56.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 28.52 | 200-d Avg | 22.41 | 1yr Est | 41.50 |
MPLT News
UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and
Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r
Canaccord Genuity analyst Sumant Kulkarni maintains MapLight Therapeutics (NASDAQ:MPLT) with a Bu
Morgan Stanley analyst Sean Laaman downgrades MapLight Therapeutics (NASDAQ:MPLT) from Overweight
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT)
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular
MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dos
Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg B
UBS analyst Ashwani Verma maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and raises the
BMO Capital analyst Malcolm Hoffman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) wit
Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See an
